Details for Patent: 4,894,240

Summary for Patent: 4,894,240

Title:	Controlled absorption diltiazem formulation for once-daily administration
Abstract:	A diltiazem pellet formulation for oral administration comprises a core of diltiazem or a pharmaceutically acceptable salt thereof in association with an organic acid, and a multi-layer membrane surrounding the core and containing a major proportion of a pharmaceutically acceptable film-forming, water insoluble synthetic polymer and a minor proportion of a pharmaceutically acceptable film-forming, water soluble synthetic polymer. The number of layers in the membrane and the ratio of the water soluble to water insoluble polymer being effective to permit release of the diltiazem from the pellet at a rate allowing controlled absorption thereof over a twenty four hour period following oral administration.
Inventor(s):	Geoghegan; Edward J. (Athlone, IE), Mulligan; Seamus (Athlone, IE), Panoz; Donald E. (Tuckerstown, BM)
Assignee:	Elan Corporation plc (Athlone, IE)
Application Number:	07/121,225
Patent Claim Types: see list of patent claims	Formulation; Compound; Dosage form; Device; Composition;

Drugs Protected by US Patent 4,894,240

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 4,894,240

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	241987
Austria	66813
Australia	2377588
Australia	615221
Australia	634660
Australia	7943591